FollowMyHealth Patient Portal

David Michael Holtzman, MD

Andrew B. and Gretchen P. Jones Professor of Neurology
Charlotte and Paul Hagemann Professor of Neurology
Chairman, Department of Neurology
Professor, Molecular Biology and Pharmacology
Neurologist-in-Chief, Barnes-Jewish Hospital

Specialty Areas

Neurology - Adult
Memory Disorders and Diagnosis
Alzheimer's Disease
Dementia

Board Certifications

Neurology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Neurology, molecular biology, pharmacology, nervous system, Alzheimer's disease, memory, brain research, cerebral blood flow, metabolism, neuroscience, lipid research, neuron, mental retardation, Down's syndrome, neonatal hypoxic-ischemia, brain disorders, spinal fluid.

  • Maps & Directions
  • Education
  • Publication & Research
  • Financial Disclosures

Maps & Directions

Maps & Directions

Center for Advanced Medicine
Memory Diagnostic Center

4921 Parkview Place
St. Louis, MO 63110

Suite: C
Floor: 6
Office Phone: (314) 286-1967
Fax: (314) 286-1985
Email: holtzman@neuro.wustl.edu

Education

Education

Residency: Neurology, University of California, San Francisco, California 1989
Medical Degree: Northwestern University, Chicago, Illinois 1985
BS: Science in Medical Education, Northwestern University, Chicago, Illinois 1983

Publication & Research

Publication & Research

Sleep in Alzheimer's Disease - Beyond Amyloid.
Holth J, Patel T, Holtzman DM
Neurobiol Sleep Circadian Rhythms. 2017 Jan; 24-14. doi: 10.1016/j.nbscr.2016.08.002.

PMID:
    28217760
    [PubMed - in process]
Related citations


Cerebrospinal fluid biomarkers of infantile congenital hydrocephalus.
Limbrick DD Jr, Baksh B, Morgan CD, Habiyaremye G, McAllister JP 2nd, Inder TE, Mercer D, Holtzman DM, Strahle J, Wallendorf MJ, Morales DM
PLoS One. 2017 Feb 17; 12(2)e0172353. doi: 10.1371/journal.pone.0172353.

PMID:
    28212403
    [PubMed - in process]
Related citations


APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice.
Pankiewicz JE, Baquero-Buitrago J, Sanchez S, Lopez-Contreras J, Kim J, Sullivan PM, Holtzman DM, Sadowski MJ
Mol Neurodegener. 2017 Jan 31; 12(1)12. doi: 10.1186/s13024-017-0156-1.

PMID:
    28143566
    [PubMed - in process]
Related citations


Erratum to: Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation.
Achariyar TM, Li B, Peng W, Verghese PB, Shi Y, McConnell E, Benraiss A, Kasper T, Song W, Takano T, Holtzman DM, Nedergaard M, Deane R
Mol Neurodegener. 2017 Jan 12; 12(1)3. doi: 10.1186/s13024-016-0147-7.

PMID:
    28081701
    [PubMed - in process]
Related citations


Antibody Therapeutics Targeting Aβ and Tau.
Gallardo G, Holtzman DM
Cold Spring Harb Perspect Med. 2017 Jan 6; pii: a024331. doi: 10.1101/cshperspect.a024331.

PMID:
    28062555
    [PubMed - as supplied by publisher]
Related citations


Reply.
Ju YS, Holtzman DM
Ann Neurol. 2017 Feb; 81(2)322-323. doi: 10.1002/ana.24849.

PMID:
    28019658
    [PubMed - in process]
Related citations


Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation.
Achariyar TM, Li B, Peng W, Verghese PB, Shi Y, McConnell E, Benraiss A, Kasper T, Song W, Takana T, Holtzman DM, Nedergaard M, Deane R
Mol Neurodegener. 2016 Dec 8; 11(1)74.

PMID:
    27931262
    [PubMed - in process]
Related citations


Mechanisms linking circadian clocks, sleep, and neurodegeneration.
Musiek ES, Holtzman DM
Science. 2016 Nov 25; 354(6315)1004-1008.

PMID:
    27885006
    [PubMed - in process]
Related citations


The Effects of Peripheral and Central High Insulin on Brain Insulin Signaling and Amyloid-β in Young and Old APP/PS1 Mice.
Stanley M, Macauley SL, Caesar EE, Koscal LJ, Moritz W, Robinson GO, Roh J, Keyser J, Jiang H, Holtzman DM
J Neurosci. 2016 Nov 16; 36(46)11704-11715.

PMID:
    27852778
    [PubMed - in process]
Related citations


Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40.
Deming Y, Black K, Carrell D, Cai Y, Del-Aguila JL, Fernandez MV, Budde J, Ma S, Saef B, Howells B, Bertelsen S, Huang KL, Sutphen CL, Tarawneh R, Fagan AM, Holtzman DM, Morris JC, Goate AM, Dougherty JD, Cruchaga C
BMC Neurol. 2016 Nov 10; 16(1)217.

PMID:
    27832767
    [PubMed - indexed for MEDLINE]
Related citations


Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels.
Babulal GM, Ghoshal N, Head D, Vernon EK, Holtzman DM, Benzinger TL, Fagan AM, Morris JC, Roe CM
Am J Geriatr Psychiatry. 2016 Nov; 24(11)1095-1104. doi: 10.1016/j.jagp.2016.04.004.

PMID:
    27426238
    [PubMed - in process]
Related citations


Tau: From research to clinical development.
Holtzman DM, Carrillo MC, Hendrix JA, Bain LJ, Catafau AM, Gault LM, Goedert M, Mandelkow E, Mandelkow EM, Miller DS, Ostrowitzki S, Polydoro M, Smith S, Wittmann M, Hutton M
Alzheimers Dement. 2016 Oct; 12(10)1033-1039. doi: 10.1016/j.jalz.2016.03.018.

PMID:
    27154059
    [PubMed - in process]
Related citations


Lumbar Cerebrospinal Fluid Biomarkers of Posthemorrhagic Hydrocephalus of Prematurity: Amyloid Precursor Protein, Soluble Amyloid Precursor Protein α, and L1 Cell Adhesion Molecule.
Morales DM, Silver SA, Morgan CD, Mercer D, Inder TE, Holtzman DM, Wallendorf MJ, Rao R, McAllister JP, Limbrick DD Jr
Neurosurgery. 2016 Aug 26;

PMID:
    27571524
    [PubMed - as supplied by publisher]
Related citations


Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes.
Chung WS, Verghese PB, Chakraborty C, Joung J, Hyman BT, Ulrich JD, Holtzman DM, Barres BA
Proc Natl Acad Sci U S A. 2016 Sep 6; 113(36)10186-91. doi: 10.1073/pnas.1609896113.

PMID:
    27559087
    [PubMed - in process]
Related citations


Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.
Gordon BA, Blazey T, Su Y, Fagan AM, Holtzman DM, Morris JC, Benzinger TL
JAMA Neurol. 2016 Oct 1; 73(10)1192-1200. doi: 10.1001/jamaneurol.2016.2642.

PMID:
    27548756
    [PubMed - in process]
Related citations


Nmnat1 protects neuronal function without altering phospho-tau pathology in a mouse model of tauopathy.
Musiek ES, Xiong DD, Patel T, Sasaki Y, Wang Y, Bauer AQ, Singh R, Finn SL, Culver JP, Milbrandt J, Holtzman DM
Ann Clin Transl Neurol. 2016 May 6; 3(6)434-42. doi: 10.1002/acn3.308.

PMID:
    27547771
    [PubMed]
Related citations


BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease.
Lim YY, Hassenstab J, Cruchaga C, Goate A, Fagan AM, Benzinger TL, Maruff P, Snyder PJ, Masters CL, Allegri R, Chhatwal J, Farlow MR, Graff-Radford NR, Laske C, Levin J, McDade E, Ringman JM, Rossor M, Salloway S, Schofield PR, Holtzman DM, Morris JC, Bateman RJ, Dominantly Inherited Alzheimer Network.
Brain. 2016 Oct; 139(Pt 10)2766-2777.

PMID:
    27521573
    [PubMed - as supplied by publisher]
Related citations


Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer's disease.
Minter MR, Zhang C, Leone V, Ringus DL, Zhang X, Oyler-Castrillo P, Musch MW, Liao F, Ward JF, Holtzman DM, Chang EB, Tanzi RE, Sisodia SS
Sci Rep. 2016 Jul 21; 630028. doi: 10.1038/srep30028.

PMID:
    27443609
    [PubMed - in process]
Related citations


Changes in insulin and insulin signaling in Alzheimer's disease: cause or consequence?
Stanley M, Macauley SL, Holtzman DM
J Exp Med. 2016 Jul 25; 213(8)1375-85. doi: 10.1084/jem.20160493.

PMID:
    27432942
    [PubMed - in process]
Related citations


Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease.
Vlassenko AG, McCue L, Jasielec MS, Su Y, Gordon BA, Xiong C, Holtzman DM, Benzinger TL, Morris JC, Fagan AM
Ann Neurol. 2016 Sep; 80(3)379-87. doi: 10.1002/ana.24719.

PMID:
    27398953
    [PubMed - in process]
Related citations

Financial Disclosures

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians work collaboratively with pharmaceutical or medical device companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our faculty physicians are paid by these commercial companies to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this web site, physicians earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

This physician reported the following earned financial interests during calendar year 2015.

Company Name: C2N Diagnostics

Royalties: > $200,000

Equity: Yes

Consulting/Advisory Board: $10,001 - $25,000

Speaker Fees:

Reporting Date: May 01, 2016


Company Name: Neurophage

Royalties:

Equity: No

Consulting/Advisory Board: $10,001 - $25,000

Speaker Fees:

Reporting Date: May 01, 2016

Areas of Research Interest

Underlying mechanisms that lead to Alzheimer's disease.